First Manhattan’s Alexion Pharmaceuticals ALXN Stock Holding History

First Manhattan’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-250	Closed	-$45K	–	1736
2021 Q2	$45K	Sell	250 -100	-29%	-$17.2K	﹤0.01%	1007
2021 Q1	$53K	Hold	350	–	–	﹤0.01%	953
2020 Q4	$54K	Hold	350	–	–	﹤0.01%	891
2020 Q3	$40K	Hold	350	–	–	﹤0.01%	917
2020 Q2	$39K	Hold	350	–	–	﹤0.01%	923
2020 Q1	$31K	Sell	350 -375	-52%	-$36.8K	﹤0.01%	940
2019 Q4	$78K	Buy	725 +625	+625%	+$66.8K	﹤0.01%	830
2019 Q3	$9K	Buy	+100	New	+$11.3K	﹤0.01%	1168
2018 Q1	–	Sell	-690	Closed	-$82K	–	1490
2017 Q4	$82K	Buy	+690	New	+$84K	﹤0.01%	895
2015 Q1	–	Sell	-19	Closed	-$3K	–	1536
2014 Q4	$3K	Buy	+19	New	+$3.52K	﹤0.01%	1390

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

First Manhattan's ALXN Position: Q3 2021 in Review

First Manhattan sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 250 shares — an estimated $45K sold.

First Manhattan first reported a position in ALXN in Q4 2014 and held it in 10 quarters. The position peaked at $82K in Q4 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

First Manhattan reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
First Manhattan sold 250 Alexion Pharmaceuticals shares in Q3 2021, an estimated $45K.
First Manhattan first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 10 quarters.
First Manhattan's Alexion Pharmaceuticals position peaked at $82K in Q4 2017.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on First Manhattan's 13F filing for Q3 2021, filed 15 Nov 2021.